<DOC>
	<DOCNO>NCT01079481</DOCNO>
	<brief_summary>The objective phase I study determine maximum tolerate dose ( MTD ) combination therapy paclitaxel everolimus small cell lung cancer patient previous treatment history .</brief_summary>
	<brief_title>Combination Anticancer Therapy Paclitaxel Everolimus Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>Small cell lung cancer ( SCLC ) account 15 % 20 % lung cancer , half patient diagnose extensive-stage disease ( ED ) . SCLC particularly aggressive form lung cancer tendency rapid tumor growth , early dissemination high frequency metastasis In study , evaluate MTD everolimus combine paclitaxel combination chemotherapy SCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm small cell lung cancer 2 . Regarding limited disease , disease patient , concurrent chemoradiation therapy , relapse progressing , patient receive first line platinumbased anticancer therapy . The disease progressing/relapsed previous treatment . 3 . Regarding extensive disease , progression/relapse disease first line platinumbased anticancer therapy confirm . 4 . Patient asymptomatic treat brain metastasis . 5 . Patients without current concomitant chemotherapy 6 . Patients without current concomitant radiotherapy 7 . Patients receive chronic treatment steroid another immunosuppressive agent . 8 . Patients least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) . 9 . Patients age 18 year old 10 . ECOG performance status 02 11 . Adequate organ function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; hemoglobin &gt; 9g/dL ; ; total bilirubin ≤1.5 UNL ; AST and/or ALT &lt; 5 UNL ; creatinine clearance ≥ 50mL/min . 12 . Patients sign date informed consent form prior specific study procedure . 13 . Patients comply schedule followup toxicity management procedure . ' 1 . Patients history treatment mTOR inhibitor 2 . Pregnant gastrointestinal problem impair absorption drug 3 . Patients could use appropriate method contraception 4 . Pregnant feeding patient 5 . Other medically ill patient 6 . Severe heart/pulmonary disease 7 . DM patient 8 . Other malignancy except cured skin cancer uterine cervix carcinoma situ 9 . High cholesterolemia great grade 3 10 . Patients symptomatic brain metastasis 11 . Chronic hepatitis liver cirrhosis ( patient HBsAg positive , IgM antiHBc positive HCV Ab positive ) 12 . Patients receive immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Relapsed Refractory Small Cell Lung Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Everolimus</keyword>
</DOC>